Biosplice’s osteoarthritis drug has failed a Phase 3 clinical trial, according to the drugmaker, significantly clouding the drug’s chances of approval and the future of a company that was once valued at $12 billion.
Presentation of OA-07 Phase 3 Long-Term Results for Lorecivivint and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Biosplice Therapeutics Inc. presents results of OA-07 Long-Term Extension Trial for its knee OA drug candidate, lorecivivint.
SAN DIEGO and SILVER SPRING, Md., Sept. 17, 2018 /PRNewswire/ -- Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq :UTHR ) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF). Deal terms include $10 million up-front, plus up to $340 million in developmental milestones and up to low double-digit royalties.